Form 4: Denali Therapeutics Executive Sells Shares to Cover Tax Obligations

Denali Therapeutics' CFO and Secretary, Alexander O. Schuth, sold shares to cover tax obligations related to vested restricted stock units.

Summary

• Alexander O. Schuth, the CFO and Secretary of Denali Therapeutics, sold a total of 15,162 shares of common stock.
• The sales occurred on January 6, 2025, and January 7, 2025.
• The shares were sold to satisfy tax obligations related to the settlement of previously vested restricted stock units.
• On January 6, 2025, 12,255 shares were sold at a weighted average price of $20.22 per share, with prices ranging from $19.91 to $20.23.
• On January 7, 2025, 2,907 shares were sold at a price of $20.81 per share.
• Following these transactions, Mr. Schuth directly owns 244,308 shares and indirectly owns 523,749 shares through The Schuth Family Trust.
• The direct holdings include 134,030 unvested restricted stock units.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction of an executive selling shares to cover tax obligations. It is neither particularly positive nor negative for the company's outlook.

Industry Context

Executive stock sales are a common occurrence, particularly around vesting periods for equity compensation. This transaction is not unusual and is related to tax obligations.

Comparison to Industry Standards

• Executive stock sales are a common practice across the biotechnology industry, often tied to vesting schedules and tax planning.
• Similar transactions are regularly reported by executives at companies like Biogen (BIIB) and Regeneron (REGN), where stock-based compensation is a significant part of executive pay.
• The sale prices are within the typical range for market transactions, and the volume of shares sold is not unusually large for an executive at this level.

Stakeholder Impact

• The stock sales may have a minor impact on the stock price, but it is unlikely to be significant given the relatively small volume of shares sold.
• The transaction does not directly impact employees, customers, or suppliers.

Key Dates

Keywords

Denali Therapeutics, DNLI, insider trading, stock sale, executive compensation, restricted stock units, tax obligations, Alexander O. Schuth